Aprepitant an advance on standard antiemetic regimen for MEC

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1468, 2004-01, pp. : 17-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiemetic Studies on the NK₁ Receptor Antagonist Aprepitant

By Stoutenburg John P. Raftopoulos Harry

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 5, 2004-09 ,pp. : 491-497

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Aprepitant: novel antiemetic brings greater benefit for chemotherapy recipients

Inpharma, Vol. 1, Iss. 1400, 2003-01 ,pp. : 11-13

Adis International

Access to resources Recommend Favorite

The neurokinin₁ receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy

By Warr David

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1653-1658

Informa Healthcare

Access to resources Recommend Favorite

DCEP an alternative to standard regimen in myeloma

Inpharma, Vol. 1, Iss. 1462, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

A pharmacokinetic, pharmacodynamic, and safety study of intravenous cyclophosphamide with an oral casopitant antiemetic regimen in cancer patients

Clinical Pharmacology In Drug Development, Vol. 3, Iss. 2, 2014-03 ,pp. : 93-100

John Wiley & Sons Inc

Access to resources Recommend Favorite